摘要
四因子凝血酶原複合濃縮劑(four-factor prothrombin complex concentrate, 4F-PCC) 含凝血因子II、VII、IX、X及蛋白質C、S,能快速逆轉維生素K拮抗劑相關出血。本案例為一名47歲男性接受二尖瓣金屬瓣膜置換術,術後第1天開始接受warfarin治療預防栓塞。術後第15天檢測國際標準化比值(international normalized ratio, INR) 達4.89且出現鮮紅色血便,評估為warfarin 相關消化道出血,醫師停用warfarin,當日及隔日各給予4F-PCC 500 IU靜脈注射,未合併用維生素K。術後第22天於臨床穩定狀況下重啟warfarin治療並於術後第33天出院。本案例處置未合併維生素K,與2018年美國血液學會(American Society of Hematology) 及2020年美國心臟學院(American College of Cardiology) 指引建議不同,但符合2022年美國-加拿大腸胃學會(American College of Gastroenterology-Canadian Association of Gastroenterology) 腸胃出血處置指引。後者認為維生素K校正INR時間較長,缺乏即時止血證據而不建議常規使用。本案例採「低固定起始劑量、按需追加」之4F-PCC策略,500 IU分2段次給予,總劑量為1,000 IU,低於仿單針對INR 4–6建議之1,850 IU (35 IU/kg) ,對金屬瓣膜高栓塞風險的患者,可兼顧止血效率與血栓安全。4F-PCC屬於速效高危藥品,須嚴格控制注射速率,本案例500 IU (20mL) 藥師建議以0.12 mL/kg/min(約4分鐘)緩慢靜脈輸注,符合仿單建議的安全規範,並展現藥師在重症照護中與其他專業合作的角色。
ABSTRACT
Four-factor prothrombin complex concentrate (4F-PCC) contains coagulation factors II, VII, IX, and X, as well as proteins C and S, and can rapidly reverse vitamin K antagonist-associated bleeding. Here, we report the case of a 47-year-old man who required 4F-PCC after mitral valve replacement with a mechanical valve, which carries the risk of thromboembolism.
On postoperative day (POD) 1, warfarin was initiated as prophylaxis for thromboembolism.
On POD 15, the patient developed hematochezia with an international normalized ratio (INR) of 4.89, consistent with warfarin-associated gastrointestinal bleeding. Warfarin was withheld and 4F-PCC (500 IU) was infused on two consecutive days without vitamin K. After stabilization, warfarin was restarted on POD 22, and the patient was discharged on POD 33.
This vitamin K–sparing approach differs from the 2018 American Society of Hematology and 2020 American College of Cardiology recommendations but aligns with the 2022 American College of Gastroenterology-Canadian Association of Gastroenterology guideline for the management of gastrointestinal bleeding, which discourages routine vitamin K administration because vitamin K has a delayed effect on INR correction and lacks evidence of immediate hemostatic benefit. Specifically, we adopted a strategy of low fixed initial dosing with on-demand 4F-PCC supplementation, administering two 500-IU doses (total 1,000 IU). This was below the label-based recommendation for an INR of 4–6 (~1,850 IU, 35 IU/kg) to balance hemostatic efficacy with thromboembolic safety in this patient with a mechanical valve.
4F-PCC is a high-alert, fast-acting agent that requires a strictly controlled infusion rate. The pharmacist in this case advised the administration of 500 IU (20 mL) via slow intravenous infusion (0.12 mL/kg/min for approximately 4 minutes), consistent with its labeling. This underscores the pharmacist’s role in the reversal strategy and medication safety.
Submitted for publication: 2025.09.23; Accepted for publication: 2026.02.27